131 related articles for article (PubMed ID: 20949468)
1. Loss of Reprimo and S100A2 expression in human gastric adenocarcinoma.
Luo J; Zhu Y; Yang G; Gong L; Wang B; Liu H
Diagn Cytopathol; 2011 Oct; 39(10):752-7. PubMed ID: 20949468
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of altered S100A2 expression in gastric cancer.
Zhao Y; Zhang TB; Wang Q
Oncol Rep; 2013 Apr; 29(4):1556-62. PubMed ID: 23337980
[TBL] [Abstract][Full Text] [Related]
3. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis.
Joo M; Lee HK; Kang YK
Anticancer Res; 2003; 23(2B):1581-8. PubMed ID: 12820426
[TBL] [Abstract][Full Text] [Related]
4. Expression of calcium-binding proteins S100A2 and S100A4 in Barrett's adenocarcinomas.
Lee OJ; Hong SM; Razvi MH; Peng D; Powell SM; Smoklin M; Moskaluk CA; El-Rifai W
Neoplasia; 2006 Oct; 8(10):843-50. PubMed ID: 17032501
[TBL] [Abstract][Full Text] [Related]
5. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer.
Biankin AV; Kench JG; Colvin EK; Segara D; Scarlett CJ; Nguyen NQ; Chang DK; Morey AL; Lee CS; Pinese M; Kuo SC; Susanto JM; Cosman PH; Lindeman GJ; Visvader JE; Nguyen TV; Merrett ND; Warusavitarne J; Musgrove EA; Henshall SM; Sutherland RL;
Gastroenterology; 2009 Aug; 137(2):558-68, 568.e1-11. PubMed ID: 19376121
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of S100A2 in lymph node metastases of head and neck cancer.
Zhang X; Hunt JL; Shin DM; Chen ZG
Head Neck; 2007 Mar; 29(3):236-43. PubMed ID: 17123307
[TBL] [Abstract][Full Text] [Related]
7. DNA damage-inducible gene, reprimo functions as a tumor suppressor and is suppressed by promoter methylation in gastric cancer.
Ooki A; Yamashita K; Yamaguchi K; Mondal A; Nishimiya H; Watanabe M
Mol Cancer Res; 2013 Nov; 11(11):1362-74. PubMed ID: 23982217
[TBL] [Abstract][Full Text] [Related]
8. Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer.
Rehman I; Cross SS; Catto JW; Leiblich A; Mukherjee A; Azzouzi AR; Leung HY; Hamdy FC
Prostate; 2005 Dec; 65(4):322-30. PubMed ID: 16015609
[TBL] [Abstract][Full Text] [Related]
9. Reprimo as a potential biomarker for early detection in gastric cancer.
Bernal C; Aguayo F; Villarroel C; Vargas M; Díaz I; Ossandon FJ; Santibáñez E; Palma M; Aravena E; Barrientos C; Corvalan AH
Clin Cancer Res; 2008 Oct; 14(19):6264-9. PubMed ID: 18829507
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of immunohistochemically-identified lymphatic and/or blood vessel tumor invasion in gastric cancer.
Kim JH; Park SS; Park SH; Kim SJ; Mok YJ; Kim CS; Lee JH; Kim YS
J Surg Res; 2010 Aug; 162(2):177-83. PubMed ID: 20031164
[TBL] [Abstract][Full Text] [Related]
11. Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis.
Ohuchida K; Mizumoto K; Miyasaka Y; Yu J; Cui L; Yamaguchi H; Toma H; Takahata S; Sato N; Nagai E; Yamaguchi K; Tsuneyoshi M; Tanaka M
J Pathol; 2007 Nov; 213(3):275-82. PubMed ID: 17940995
[TBL] [Abstract][Full Text] [Related]
12. Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters.
Saito H; Osaki T; Murakami D; Sakamoto T; Kanaji S; Ohro S; Tatebe S; Tsujitani S; Ikeguchi M
J Surg Oncol; 2007 Feb; 95(2):123-8. PubMed ID: 17262742
[TBL] [Abstract][Full Text] [Related]
13. Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma.
Chou YY; Jeng YM; Lee TT; Hu FC; Kao HL; Lin WC; Lai PL; Hu RH; Yuan RH
Ann Surg Oncol; 2007 Oct; 14(10):2748-58. PubMed ID: 17680316
[TBL] [Abstract][Full Text] [Related]
14. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma.
Bachet JB; Maréchal R; Demetter P; Bonnetain F; Cros J; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Vaillant JC; André T; Closset J; Salmon I; Emile JF; Van Laethem JL
Eur J Cancer; 2013 Aug; 49(12):2643-53. PubMed ID: 23726265
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes.
Matsubara D; Niki T; Ishikawa S; Goto A; Ohara E; Yokomizo T; Heizmann CW; Aburatani H; Moriyama S; Moriyama H; Nishimura Y; Funata N; Fukayama M
Cancer Sci; 2005 Dec; 96(12):844-57. PubMed ID: 16367903
[TBL] [Abstract][Full Text] [Related]
16. S100A2 overexpression is frequently observed in esophageal squamous cell carcinoma.
Imazawa M; Hibi K; Fujitake S; Kodera Y; Ito K; Akiyama S; Nakao A
Anticancer Res; 2005; 25(2B):1247-50. PubMed ID: 15865073
[TBL] [Abstract][Full Text] [Related]
17. Mixed-histologic-type submucosal invasive gastric cancer as a risk factor for lymph node metastasis: feasibility of endoscopic submucosal dissection.
Hanaoka N; Tanabe S; Mikami T; Okayasu I; Saigenji K
Endoscopy; 2009 May; 41(5):427-32. PubMed ID: 19418397
[TBL] [Abstract][Full Text] [Related]
18. E-cadherin expression as predictive marker of proximal resection line involvement for advanced carcinoma of the gastric cardia.
Polkowski WP; Skomra DG; Mielko J; Wallner GT; Szumiło J; Zinkiewicz K; Korobowicz EM; van Lanschot JJ
Eur J Surg Oncol; 2004 Dec; 30(10):1084-92. PubMed ID: 15522555
[TBL] [Abstract][Full Text] [Related]
19. Expression and prognostic significance of S100A2 protein in squamous cell carcinoma of the esophagus.
Kyriazanos ID; Tachibana M; Dhar DK; Shibakita M; Ono T; Kohno H; Nagasue N
Oncol Rep; 2002; 9(3):503-10. PubMed ID: 11956617
[TBL] [Abstract][Full Text] [Related]
20. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer.
Shun CT; Wu MS; Lin JT; Chen SY; Wang HP; Lee WJ; Wang TH; Chuang SM
Hepatogastroenterology; 1997; 44(14):604-9. PubMed ID: 9164544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
